Agronomic portal Agronom.info
Categories
Language
Currency
My account
Rapeseed

Safran

Diseases
Sclerotinia, Phomosis
Country
Germany
Registration Year
2011
Manufacturer
Deutsche Saatveredelung AG
Offers: 1
Where to buy
Price range
950 - 950 UAH
Views
6
Reviews
0
Producer
Deutsche Saatveredelung AG
Description Safran
Safran — a high-yielding winter rapeseed hybrid, designed for cultivation under various climatic conditions, including arid regions. It features a deeply developed and strong root system, providing high stress tolerance and adaptation to adverse environmental factors. The hybrid is characterized by high and stable yield, reaching potentially 73 c/ha, with an average actual yield of around 48 c/ha, making it a profitable choice for farmers.

Safran has a medium-early maturity period — approximately 300 days, enabling effective planning of agronomic activities. The hybrid is resistant to broad-spectrum herbicides, particularly glyphosate, which simplifies weed control and reduces the cost of crop treatments. For disease and pest protection, fungicide and insecticide treatments are applied, including thiamethoxam and imidacloprid, contributing to plant health and increased yield.

Additionally, Safran demonstrates high resistance to major diseases and stress factors: winter hardiness is rated at 9 points, lodging resistance at 10, and tolerance to phoma and sclerotinia at 9. The hybrid also exhibits high drought tolerance and resistance to pod cracking, ensuring crop preservation and quality. The planting unit contains 1,500,000 seeds, sufficient for treating 2.5–3.0 hectares, with seed weight of 9 kg.
Specifications Safran
Diseases
Sclerotinia
Sclerotiniosis
Phomosis
Phomosis
Type of Rape
Winter rape
Hybrid Type
Simple Linear
Growing Season
290-300 days
Yield Potential
60-70 ц/га
Herbicide Resistance
Clearfield
Country
Germany
Registration Year
2011
Catalog
Varieties
Technical Crops
Manufacturer
Deutsche Saatveredelung AG
Where to buy Safran
Loading...
Reviews Safran
0comments
Sort by:Popular first
No comments yet.